Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIBOCICLIB Cause Carcinoembryonic antigen increased? 143 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 143 reports of Carcinoembryonic antigen increased have been filed in association with RIBOCICLIB (KISQALI). This represents 0.5% of all adverse event reports for RIBOCICLIB.

143
Reports of Carcinoembryonic antigen increased with RIBOCICLIB
0.5%
of all RIBOCICLIB reports
15
Deaths
30
Hospitalizations

How Dangerous Is Carcinoembryonic antigen increased From RIBOCICLIB?

Of the 143 reports, 15 (10.5%) resulted in death, 30 (21.0%) required hospitalization, and 9 (6.3%) were considered life-threatening.

Is Carcinoembryonic antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 143 reports have been filed with the FAERS database.

What Other Side Effects Does RIBOCICLIB Cause?

Neutropenia (3,585) Nausea (3,404) Fatigue (3,327) Malignant neoplasm progression (2,468) Death (2,452) Vomiting (1,953) Diarrhoea (1,830) White blood cell count decreased (1,683) Pain (1,637) Metastases to bone (1,538)

What Other Drugs Cause Carcinoembryonic antigen increased?

LETROZOLE (115) CAPECITABINE (113) FULVESTRANT (105) BEVACIZUMAB (102) REGORAFENIB (91) OXALIPLATIN (88) OSIMERTINIB (82) PALBOCICLIB (78) FLUOROURACIL (71) PANITUMUMAB (69)

Which RIBOCICLIB Alternatives Have Lower Carcinoembryonic antigen increased Risk?

RIBOCICLIB vs RIBOFLAVIN RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE RIBOCICLIB vs RIFABUTIN RIBOCICLIB vs RIFAMPICIN

Related Pages

RIBOCICLIB Full Profile All Carcinoembryonic antigen increased Reports All Drugs Causing Carcinoembryonic antigen increased RIBOCICLIB Demographics